ArticleThe Journal of clinical endocrinology and metabolism2011
Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location.
Article in The Journal of clinical endocrinology and metabolism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 106 citations in OpenAlex.
- Genotype-dependent [European journal of nuclear medicine and molecular imaging · 2026Article
- Evaluation of differences in presentation and postoperative outcomes after adrenalectomy for pheochromocytoma according to age.Endocrine connections · 2026Article
- Clinical and genetic features of older patients with pheochromocytomas and paragangliomas: A multicenter retrospective study.Journal of endocrinological investigation · 2026Article
- Quantitative [EJNMMI reports · 2025Article
- [European journal of nuclear medicine and molecular imaging · 2025Article
- Adrenal causes of endocrine hypertension in childhood or adolescence.Journal of endocrinological investigation · 2025Review
- A Rare Case of Metastatic Carotid Body Paraganglioma: A 7-Year Asymptomatic Period.Case reports in oncological medicine · 2025Article
- Prevention and management of hypertensive crises in children with pheochromocytoma and paraganglioma.Frontiers in endocrinology · 2024Review
- Paragangliomas and Anemia: Literature Review and Case Report.Medicina (Kaunas, Lithuania) · 2023Review
- HIF and MYC signaling in adrenal neoplasms of the neural crest: implications for pediatrics.Frontiers in endocrinology · 2023Review
- Clinical presentation of sporadic and hereditary pheochromocytoma/paraganglioma.Endocrine oncology (Bristol, England) · 2023Article
- Intratumoral immunotherapy of murine pheochromocytoma shows no age-dependent differences in its efficacy.Frontiers in endocrinology · 2023Article
- Influence of duration of preoperative treatment with phenoxybenzamine and secretory phenotypes on perioperative hemodynamics and postoperative outcomes in pheochromocytoma and paraganglioma.Frontiers in endocrinology · 2023Article
- Epistaxis, paroxysmal anxiety episodes, and hypertension in a child withClinical case reports · 2022Article
- Benign phaeochromocytoma presenting with recurrent spells and negative biochemical screening.BMJ case reports · 2022Article
- Hypermetabolism and Substrate Utilization Rates in Pheochromocytoma and Functional Paraganglioma.Biomedicines · 2022Article
- Reply to Letter to the Editor: "Pheochromocytoma and Takotsubo Syndrome: An Ominous Duo".Anatolian journal of cardiology · 2022Article
- PGL4 syndrome in a patient with synchronous paraganglioma-pheochromocytoma.BMJ case reports · 2022Article
- Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine.Endocrine-related cancer · 2022Article
- Biochemical Diagnosis of Catecholamine-Producing Tumors of Childhood: Neuroblastoma, Pheochromocytoma and Paraganglioma.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 4 countries.
Funding
Abstract
contextPheochromocytomas and paragangliomas (PPGLs) are diagnosed earlier in patients with hereditary than sporadic disease. Whether other factors influence age at diagnosis is unclear.
objectiveWe examined ages at which PPGLs were diagnosed according to different catecholamine phenotypes and locations of tumors. DESIGN &
settingRetrospective multicenter study. PATIENTS: Patients with PPGLs included 172 with and 183 without identified germline mutations or hereditary syndromes. BIOCHEMICAL MEASUREMENTS: Differences in plasma concentrations of metanephrine, a metabolite of epinephrine, were used to distinguish epinephrine-producing tumors from those lacking epinephrine production.
resultsPatients with epinephrine-producing tumors were diagnosed 11 yr later (P < 0.001) than those with tumors lacking appreciable epinephrine production. Among patients without evidence of a hereditary condition, those with and without epinephrine-producing tumors had respective mean ± se ages of 50 ± 2 and 42 ± 2 yr (P < 0.001) at diagnosis. Patients with multiple endocrine neoplasia type 2 and neurofibromatosis type 1, all with epinephrine-producing tumors, were similarly diagnosed with disease at a later age than patients with tumors that lacked appreciable epinephrine production secondary to mutations of von Hippel-Lindau and succinate dehydrogenase genes (40 ± 2 vs. 31 ± 1 yr, P < 0.001). Among the latter patients, those with multifocal tumors were diagnosed earlier than those with solitary tumors (19 ± 3 vs. 34 ± 2 yr, P < 0.001).
conclusionsThe variations in ages at diagnosis associated with different tumor catecholamine phenotypes and locations suggest origins of PPGLs from different chromaffin progenitor cells with variable susceptibility to disease causing mutations. Different optimal age cut-offs for mutation testing are indicated for patients with and without epinephrine-producing tumors (44-49 vs. 30-35 yr, respectively).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.